Qiagen (QGEN) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Qiagen (NYSE:QGEN) from a hold rating to a buy rating in a research report report published on Monday.

A number of other equities research analysts have also recently commented on QGEN. DZ Bank reissued a neutral rating on shares of Qiagen in a report on Thursday, April 5th. Morgan Stanley decreased their price target on Qiagen from $39.00 to $37.00 and set an overweight rating on the stock in a report on Wednesday, April 11th. Deutsche Bank reissued a buy rating and set a $40.00 price target (up from $38.00) on shares of Qiagen in a report on Tuesday, April 24th. Commerzbank reissued a buy rating on shares of Qiagen in a report on Thursday, May 3rd. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of Qiagen in a report on Thursday, May 3rd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $38.50.

Get Qiagen alerts:

Shares of Qiagen stock opened at $36.13 on Monday. Qiagen has a one year low of $30.20 and a one year high of $37.61. The firm has a market capitalization of $8.25 billion, a P/E ratio of 27.58, a P/E/G ratio of 2.25 and a beta of 1.12. The company has a current ratio of 2.14, a quick ratio of 1.94 and a debt-to-equity ratio of 0.52.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.02. The business had revenue of $343.57 million for the quarter, compared to analysts’ expectations of $340.10 million. Qiagen had a return on equity of 11.91% and a net margin of 3.79%. analysts forecast that Qiagen will post 1.34 earnings per share for the current year.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

To view ValuEngine’s full report, visit ValuEngine’s official website.